首页 | 官方网站   微博 | 高级检索  
     

经颞浅动脉灌注化疗治疗无法切除的晚期上颌恶性肿瘤的疗效分析
引用本文:王润湘,李朝军,吴云腾,吕炯,汪东方,任国欣,郭伟. 经颞浅动脉灌注化疗治疗无法切除的晚期上颌恶性肿瘤的疗效分析[J]. 临床肿瘤学杂志, 2014, 19(7): 621-624
作者姓名:王润湘  李朝军  吴云腾  吕炯  汪东方  任国欣  郭伟
作者单位:200011.上海 上海交通大学附属第九人民医院口腔颌面-头颈肿瘤科
基金项目:上海市科委资助项目(12140902201);上海交大医工交叉研究基金资助项目(YG2012MS50)
摘    要:目的 观察经颞浅动脉灌注化疗治疗无法切除的晚期上颌恶性肿瘤的疗效和毒副反应。方法16例无法切除局部晚期上颌恶性肿瘤患者,行选择性颞浅动脉插管后,根据化疗方案用微量输液泵经导管远心端药池输注相应化疗药物:多西他赛60~75mg/m2匀速灌注2h,d1;顺铂75mg/m2大剂量冲击2h,d1;氟尿嘧啶500mg/m2连续灌注120h,d1~d5;吡柔比星25mg/m2匀速灌注2h,d1~d3;吉西他滨1000mg/m2连续滴注30min,d1、d8。21天为1个周期,2个周期分别采用RECIST 1.1标准和NCI CTC 3.0标准评价近期疗效和毒副反应并随访远期生存情况。结果16例均可评价近期疗效,其中CR 1例,PR 10例,SD 5例,RR为68.8%,DCR为100.0%。14例获随访(87.5%),中位生存期和无进展生存期分别为26.0个月和4.0个月。全组未有4级毒副反应发生,无治疗相关性死亡,3级毒副反应主要为1例耳廓部分坏死、3例贫血及1例骨髓抑制,其余均为1~2级。结论 无法切除的晚期上颌恶性肿瘤经动脉灌注化疗后能够取得较为满意的治疗效果,毒副反应可耐受。

关 键 词:颞浅动脉  动脉灌注化疗  上颌恶性肿瘤  疗效
收稿时间:2013-11-19
修稿时间:2013-11-19

Effect of continuous infusion chemotherapy via superficial temporal artery on unresectable advanced maxil-lary malignant tumor
WANG Runxiang,LI Chaojun,WU Yunteng,LYU Jiong,WANG Dongfang,REN Guoxin,GUO Wei. Effect of continuous infusion chemotherapy via superficial temporal artery on unresectable advanced maxil-lary malignant tumor[J]. Chinese Clinical Oncology, 2014, 19(7): 621-624
Authors:WANG Runxiang  LI Chaojun  WU Yunteng  LYU Jiong  WANG Dongfang  REN Guoxin  GUO Wei
Affiliation:Department of Oral and Maxillofacial-Head & Neck Oncology, Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, China
Abstract:Objective To observe the curative effect and side effects of continuous infusion chemotherapy via superficial tem-poral artery on the maxillary malignant tumors. Methods Sixteen patients with unresectable advanced maxillary malignant tumor were enrolled in this study. After implantation of catheter into the superficial temporal artery, the patients received corresponding chemother-apy drugs via micro-infusion pump of drug pool at distal end of the catheter. The chemotherapy drugs were used as follow:docetaxel 60-75mg/m2 , uniform perfusion for 2h, d1;cisplatin 75mg/m2 , high dose pulse for 2h, d1;fluorouracil 500mg/m2 , continuous infusion for 120h, d1-d5;pirarubicin 25mg/m2 , uniform perfusion for 2h, d1-d3;gemcitabine 1000mg/m2 , infusion for 30min, d1 , d8 . Twen-ty-one days was a cycle. The RECIST 1.1 and NCI CTC 3.0 criteria were employed to evaluate short-term effect and adverse reaction after two cycles. The patients were followed up for long-term survival. Results All patients were evaluable with 1 case of CR, 10 of PR and 5 of SD. The RR(CR+PR) and DCR(CR+PR+SD) were 68.8% and 100.0%. In 14 cases(87.5%) followed up, the median overall survival and progression-free survival were 26.0 and 4.0 months, respectively. No treatment-related deaths and grade 4 toxicities were observed. The common grade 3 toxicities include 1 case of ear necrosis, 3 cases of anemia and 1 case of bone marrow suppression. The rest were all grade 1-2. Conclusion The treatment of unresectable advanced maxillary malignant tumor of continuous infusion chemotherapy via superficial temporal artery had satisfying effect with tolerable side effects.
Keywords:Superficial temporal artery  Arterial infusion chemotherapy  Maxillary malignant tumor  Clinical effect
本文献已被 维普 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号